Concepts (256)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retinopathy of Prematurity | 32 | 2025 | 75 | 10.480 |
Why?
|
| Retinal Detachment | 26 | 2025 | 59 | 5.750 |
Why?
|
| Bevacizumab | 23 | 2024 | 254 | 4.390 |
Why?
|
| Angiogenesis Inhibitors | 23 | 2024 | 278 | 3.780 |
Why?
|
| Laser Coagulation | 21 | 2025 | 54 | 2.820 |
Why?
|
| Fluorescein Angiography | 22 | 2024 | 77 | 2.720 |
Why?
|
| Visual Acuity | 24 | 2025 | 195 | 1.990 |
Why?
|
| Infant, Newborn | 29 | 2025 | 2427 | 1.600 |
Why?
|
| Retina | 12 | 2022 | 212 | 1.460 |
Why?
|
| Retinal Telangiectasis | 4 | 2024 | 5 | 1.370 |
Why?
|
| Optic Nerve | 7 | 2015 | 35 | 1.320 |
Why?
|
| Vitrectomy | 13 | 2022 | 46 | 1.300 |
Why?
|
| Intravitreal Injections | 17 | 2024 | 67 | 1.280 |
Why?
|
| Eye Abnormalities | 5 | 2015 | 40 | 1.200 |
Why?
|
| Connective Tissue Diseases | 4 | 2025 | 75 | 1.160 |
Why?
|
| Gestational Age | 15 | 2025 | 328 | 1.150 |
Why?
|
| Tomography, Optical Coherence | 10 | 2024 | 123 | 1.130 |
Why?
|
| Retinal Vessels | 8 | 2015 | 50 | 1.050 |
Why?
|
| Vitreous Body | 6 | 2018 | 52 | 1.000 |
Why?
|
| Retinal Ganglion Cells | 4 | 2015 | 71 | 0.970 |
Why?
|
| Eye Diseases, Hereditary | 2 | 2021 | 8 | 0.850 |
Why?
|
| Retinal Diseases | 7 | 2018 | 80 | 0.840 |
Why?
|
| Infant, Premature, Diseases | 3 | 2021 | 78 | 0.810 |
Why?
|
| Retrospective Studies | 29 | 2025 | 10132 | 0.810 |
Why?
|
| Infant | 17 | 2025 | 3156 | 0.780 |
Why?
|
| Nerve Fibers | 2 | 2015 | 40 | 0.770 |
Why?
|
| Hemangioblastoma | 2 | 2020 | 15 | 0.770 |
Why?
|
| von Hippel-Lindau Disease | 2 | 2020 | 16 | 0.760 |
Why?
|
| Follow-Up Studies | 15 | 2025 | 3815 | 0.710 |
Why?
|
| Child | 22 | 2024 | 7273 | 0.710 |
Why?
|
| Humans | 74 | 2025 | 93138 | 0.700 |
Why?
|
| Vitreous Hemorrhage | 5 | 2022 | 11 | 0.700 |
Why?
|
| Retinal Neoplasms | 2 | 2019 | 12 | 0.700 |
Why?
|
| Arthritis | 4 | 2025 | 47 | 0.690 |
Why?
|
| Hearing Loss, Sensorineural | 4 | 2025 | 49 | 0.680 |
Why?
|
| Vascular Endothelial Growth Factor A | 9 | 2024 | 391 | 0.670 |
Why?
|
| Infant, Premature | 9 | 2023 | 293 | 0.670 |
Why?
|
| Fovea Centralis | 2 | 2019 | 19 | 0.650 |
Why?
|
| Scleral Buckling | 7 | 2020 | 14 | 0.610 |
Why?
|
| Fundus Oculi | 6 | 2024 | 26 | 0.600 |
Why?
|
| Antibodies, Monoclonal, Humanized | 8 | 2014 | 1000 | 0.580 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 422 | 0.530 |
Why?
|
| Male | 38 | 2025 | 44360 | 0.520 |
Why?
|
| Lasers | 3 | 2023 | 99 | 0.510 |
Why?
|
| Female | 37 | 2025 | 48547 | 0.510 |
Why?
|
| Blindness | 3 | 2014 | 39 | 0.500 |
Why?
|
| Antibodies, Monoclonal | 4 | 2012 | 1385 | 0.500 |
Why?
|
| Child, Preschool | 12 | 2024 | 3781 | 0.440 |
Why?
|
| Macula Lutea | 1 | 2015 | 17 | 0.440 |
Why?
|
| Retinal Perforations | 3 | 2022 | 13 | 0.420 |
Why?
|
| Recurrence | 8 | 2018 | 1188 | 0.400 |
Why?
|
| Retinal Vein Occlusion | 1 | 2013 | 6 | 0.400 |
Why?
|
| Ocular Hypotension | 2 | 2011 | 4 | 0.400 |
Why?
|
| Retinal Artery Occlusion | 1 | 2013 | 12 | 0.400 |
Why?
|
| Retinal Artery | 1 | 2012 | 3 | 0.370 |
Why?
|
| Retinal Vein | 1 | 2012 | 2 | 0.370 |
Why?
|
| Silicone Oils | 2 | 2020 | 2 | 0.350 |
Why?
|
| Adolescent | 15 | 2024 | 9550 | 0.350 |
Why?
|
| Diffusion of Innovation | 1 | 2012 | 77 | 0.350 |
Why?
|
| Cytomegalovirus Retinitis | 1 | 2011 | 5 | 0.350 |
Why?
|
| Microphthalmos | 1 | 2011 | 7 | 0.350 |
Why?
|
| Conjunctiva | 1 | 2011 | 14 | 0.340 |
Why?
|
| Lasers, Semiconductor | 1 | 2011 | 2 | 0.340 |
Why?
|
| Septo-Optic Dysplasia | 3 | 2019 | 6 | 0.330 |
Why?
|
| Microsurgery | 1 | 2011 | 100 | 0.320 |
Why?
|
| Choroidal Neovascularization | 2 | 2014 | 21 | 0.310 |
Why?
|
| Neovascularization, Pathologic | 1 | 2012 | 353 | 0.310 |
Why?
|
| Macular Degeneration | 1 | 2010 | 44 | 0.310 |
Why?
|
| Uveitis | 1 | 2010 | 35 | 0.300 |
Why?
|
| Intraocular Pressure | 5 | 2011 | 61 | 0.280 |
Why?
|
| Retinal Necrosis Syndrome, Acute | 1 | 2007 | 3 | 0.270 |
Why?
|
| Herpes Zoster Ophthalmicus | 1 | 2007 | 3 | 0.270 |
Why?
|
| Herpesvirus 3, Human | 1 | 2007 | 21 | 0.260 |
Why?
|
| Abnormalities, Multiple | 2 | 2011 | 229 | 0.250 |
Why?
|
| Infant, Extremely Low Birth Weight | 4 | 2016 | 26 | 0.240 |
Why?
|
| Retinal Degeneration | 2 | 2010 | 28 | 0.240 |
Why?
|
| Adult | 18 | 2024 | 27850 | 0.240 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2007 | 98 | 0.230 |
Why?
|
| Eye Infections, Fungal | 2 | 2017 | 12 | 0.230 |
Why?
|
| Uveoparotid Fever | 1 | 2005 | 1 | 0.230 |
Why?
|
| Osteoporosis | 1 | 2007 | 129 | 0.230 |
Why?
|
| Ophthalmoplegia | 1 | 2005 | 12 | 0.230 |
Why?
|
| Treatment Outcome | 9 | 2024 | 9074 | 0.220 |
Why?
|
| Porphyrins | 1 | 2004 | 36 | 0.210 |
Why?
|
| Glioma | 1 | 2007 | 298 | 0.210 |
Why?
|
| Photosensitizing Agents | 1 | 2004 | 52 | 0.210 |
Why?
|
| Neuroprotective Agents | 1 | 2005 | 94 | 0.210 |
Why?
|
| Adjuvants, Immunologic | 1 | 2005 | 174 | 0.200 |
Why?
|
| Cataract Extraction | 2 | 2016 | 31 | 0.200 |
Why?
|
| Lens, Crystalline | 3 | 2017 | 66 | 0.200 |
Why?
|
| Photochemotherapy | 1 | 2004 | 100 | 0.200 |
Why?
|
| Oxygen Consumption | 1 | 2004 | 233 | 0.190 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2023 | 47 | 0.190 |
Why?
|
| Regional Blood Flow | 2 | 2013 | 183 | 0.190 |
Why?
|
| Perfusion | 1 | 2004 | 260 | 0.180 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 59 | 0.170 |
Why?
|
| Injections | 3 | 2010 | 121 | 0.170 |
Why?
|
| Peptides | 1 | 2005 | 653 | 0.170 |
Why?
|
| Young Adult | 7 | 2024 | 6922 | 0.170 |
Why?
|
| Retinal Neovascularization | 2 | 2011 | 4 | 0.170 |
Why?
|
| Middle Aged | 13 | 2020 | 27539 | 0.170 |
Why?
|
| Retinal Dysplasia | 2 | 2010 | 3 | 0.170 |
Why?
|
| Eye Injuries | 1 | 2020 | 15 | 0.160 |
Why?
|
| Optic Disk | 1 | 2000 | 14 | 0.160 |
Why?
|
| Hearing Loss | 2 | 2019 | 64 | 0.160 |
Why?
|
| Time Factors | 6 | 2020 | 5380 | 0.150 |
Why?
|
| Intraoperative Complications | 2 | 2011 | 191 | 0.150 |
Why?
|
| Endophthalmitis | 2 | 2017 | 18 | 0.150 |
Why?
|
| Vision, Low | 1 | 2019 | 15 | 0.150 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2022 | 277 | 0.150 |
Why?
|
| Fluoresceins | 1 | 2018 | 43 | 0.140 |
Why?
|
| Hypoxia | 1 | 2004 | 672 | 0.140 |
Why?
|
| Cerebral Palsy | 1 | 2019 | 95 | 0.140 |
Why?
|
| Loeys-Dietz Syndrome | 1 | 2018 | 21 | 0.140 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 1519 | 0.140 |
Why?
|
| Self-Injurious Behavior | 1 | 2020 | 114 | 0.140 |
Why?
|
| HIV Infections | 1 | 2007 | 952 | 0.140 |
Why?
|
| Lens Diseases | 1 | 2017 | 2 | 0.130 |
Why?
|
| Candida albicans | 1 | 2017 | 32 | 0.130 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2018 | 97 | 0.130 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2017 | 15 | 0.130 |
Why?
|
| Odds Ratio | 1 | 2019 | 709 | 0.130 |
Why?
|
| Candidiasis | 1 | 2017 | 39 | 0.130 |
Why?
|
| Abscess | 1 | 2017 | 94 | 0.130 |
Why?
|
| Aged, 80 and over | 5 | 2014 | 7039 | 0.120 |
Why?
|
| Vitreoretinal Surgery | 1 | 2016 | 8 | 0.120 |
Why?
|
| Disease Progression | 4 | 2019 | 1529 | 0.120 |
Why?
|
| Aged | 10 | 2020 | 20398 | 0.120 |
Why?
|
| Ischemia | 2 | 2010 | 252 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2018 | 941 | 0.110 |
Why?
|
| Risk Factors | 1 | 2025 | 5901 | 0.110 |
Why?
|
| Subretinal Fluid | 1 | 2014 | 2 | 0.100 |
Why?
|
| Genetic Diseases, X-Linked | 2 | 2010 | 36 | 0.100 |
Why?
|
| Reference Values | 2 | 2012 | 603 | 0.100 |
Why?
|
| Histoplasmosis | 1 | 2014 | 27 | 0.100 |
Why?
|
| Functional Laterality | 2 | 2011 | 204 | 0.100 |
Why?
|
| Blood Flow Velocity | 1 | 2013 | 177 | 0.100 |
Why?
|
| Coloboma | 1 | 2012 | 12 | 0.100 |
Why?
|
| Retinal Photoreceptor Cell Outer Segment | 1 | 2012 | 3 | 0.090 |
Why?
|
| Retinal Photoreceptor Cell Inner Segment | 1 | 2012 | 4 | 0.090 |
Why?
|
| Combined Modality Therapy | 3 | 2011 | 1719 | 0.090 |
Why?
|
| Lissencephaly | 1 | 2012 | 24 | 0.090 |
Why?
|
| Collagen Type IX | 1 | 2011 | 1 | 0.090 |
Why?
|
| Lens Implantation, Intraocular | 1 | 2011 | 23 | 0.090 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2015 | 1269 | 0.090 |
Why?
|
| Genes, Recessive | 1 | 2011 | 85 | 0.080 |
Why?
|
| Hemangioma | 1 | 2011 | 62 | 0.080 |
Why?
|
| Shaken Baby Syndrome | 1 | 2010 | 1 | 0.080 |
Why?
|
| Artificial Organs | 1 | 2010 | 4 | 0.080 |
Why?
|
| Ofloxacin | 1 | 2010 | 5 | 0.080 |
Why?
|
| Levofloxacin | 1 | 2010 | 9 | 0.080 |
Why?
|
| Acetamides | 1 | 2010 | 26 | 0.080 |
Why?
|
| Oxazolidinones | 1 | 2010 | 11 | 0.080 |
Why?
|
| Glaucoma Drainage Implants | 1 | 2010 | 11 | 0.080 |
Why?
|
| Ranibizumab | 2 | 2024 | 14 | 0.080 |
Why?
|
| Cornea | 1 | 2010 | 54 | 0.080 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2010 | 10 | 0.080 |
Why?
|
| Suture Techniques | 1 | 2011 | 137 | 0.080 |
Why?
|
| Body Fluids | 1 | 2010 | 35 | 0.080 |
Why?
|
| Postoperative Complications | 2 | 2011 | 2552 | 0.080 |
Why?
|
| Retreatment | 1 | 2010 | 104 | 0.080 |
Why?
|
| Glaucoma, Neovascular | 1 | 2009 | 4 | 0.080 |
Why?
|
| Eye Proteins | 1 | 2010 | 130 | 0.080 |
Why?
|
| Mutation | 3 | 2011 | 4265 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2010 | 753 | 0.070 |
Why?
|
| Prosthesis Implantation | 1 | 2010 | 133 | 0.070 |
Why?
|
| Prednisone | 2 | 2010 | 242 | 0.070 |
Why?
|
| HIV-2 | 1 | 2007 | 4 | 0.070 |
Why?
|
| Foscarnet | 1 | 2007 | 9 | 0.070 |
Why?
|
| Ganciclovir | 1 | 2007 | 34 | 0.070 |
Why?
|
| Vitreoretinopathy, Proliferative | 2 | 2018 | 4 | 0.070 |
Why?
|
| Valine | 1 | 2007 | 46 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 1 | 2010 | 501 | 0.070 |
Why?
|
| Acyclovir | 1 | 2007 | 35 | 0.070 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2007 | 73 | 0.070 |
Why?
|
| Glucocorticoids | 2 | 2010 | 360 | 0.060 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2007 | 3 | 0.060 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-5 | 1 | 2007 | 4 | 0.060 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2007 | 72 | 0.060 |
Why?
|
| Infusions, Intravenous | 1 | 2007 | 400 | 0.060 |
Why?
|
| Hyperplasia | 1 | 2007 | 146 | 0.060 |
Why?
|
| Fetal Blood | 1 | 2007 | 94 | 0.060 |
Why?
|
| HIV-1 | 1 | 2007 | 173 | 0.060 |
Why?
|
| Syndrome | 1 | 2007 | 432 | 0.060 |
Why?
|
| Accommodation, Ocular | 1 | 2005 | 3 | 0.060 |
Why?
|
| Anisocoria | 1 | 2005 | 2 | 0.060 |
Why?
|
| Stilbamidines | 1 | 2005 | 1 | 0.060 |
Why?
|
| Axotomy | 1 | 2005 | 9 | 0.060 |
Why?
|
| Glatiramer Acetate | 1 | 2005 | 14 | 0.060 |
Why?
|
| Collagen Type XI | 1 | 2024 | 2 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 833 | 0.050 |
Why?
|
| Collagen Type II | 1 | 2024 | 16 | 0.050 |
Why?
|
| Antiviral Agents | 1 | 2007 | 364 | 0.050 |
Why?
|
| Cell Count | 1 | 2005 | 195 | 0.050 |
Why?
|
| Rats, Wistar | 1 | 2005 | 300 | 0.050 |
Why?
|
| Algorithms | 2 | 2012 | 1948 | 0.050 |
Why?
|
| Cell Death | 1 | 2005 | 252 | 0.050 |
Why?
|
| Cats | 1 | 2004 | 281 | 0.050 |
Why?
|
| Fluorescent Dyes | 1 | 2005 | 255 | 0.050 |
Why?
|
| Catheterization | 1 | 2004 | 217 | 0.050 |
Why?
|
| Smartphone | 1 | 2023 | 52 | 0.050 |
Why?
|
| Insurance, Health | 1 | 2023 | 175 | 0.050 |
Why?
|
| Exudates and Transudates | 2 | 2013 | 13 | 0.040 |
Why?
|
| Energy Metabolism | 1 | 2004 | 299 | 0.040 |
Why?
|
| Endotamponade | 1 | 2020 | 4 | 0.040 |
Why?
|
| Trauma Severity Indices | 1 | 2020 | 46 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2020 | 315 | 0.040 |
Why?
|
| Angiography | 1 | 2020 | 192 | 0.040 |
Why?
|
| Phenotype | 2 | 2019 | 2545 | 0.040 |
Why?
|
| Administration, Ophthalmic | 1 | 2019 | 8 | 0.040 |
Why?
|
| Refraction, Ocular | 1 | 2019 | 11 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2010 | 655 | 0.040 |
Why?
|
| Rats | 1 | 2005 | 4028 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 543 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 2017 | 122 | 0.030 |
Why?
|
| Persistent Hyperplastic Primary Vitreous | 1 | 2016 | 1 | 0.030 |
Why?
|
| Retinoschisis | 1 | 2016 | 3 | 0.030 |
Why?
|
| Internationality | 1 | 2016 | 78 | 0.030 |
Why?
|
| Operative Time | 1 | 2016 | 167 | 0.030 |
Why?
|
| Cataract | 1 | 2016 | 87 | 0.030 |
Why?
|
| Animals | 2 | 2005 | 27973 | 0.030 |
Why?
|
| Anesthesia | 1 | 2016 | 173 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2016 | 753 | 0.030 |
Why?
|
| Ophthalmoscopy | 1 | 2012 | 11 | 0.020 |
Why?
|
| Prognosis | 1 | 2019 | 3891 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2012 | 291 | 0.020 |
Why?
|
| Fibrosis | 1 | 2012 | 228 | 0.020 |
Why?
|
| Walker-Warburg Syndrome | 1 | 2011 | 5 | 0.020 |
Why?
|
| Hydrocephalus | 1 | 2012 | 78 | 0.020 |
Why?
|
| N-Acetylglucosaminyltransferases | 1 | 2011 | 14 | 0.020 |
Why?
|
| Amniocentesis | 1 | 2010 | 31 | 0.020 |
Why?
|
| Linezolid | 1 | 2010 | 4 | 0.020 |
Why?
|
| Aqueous Humor | 1 | 2010 | 21 | 0.020 |
Why?
|
| Birth Weight | 1 | 2011 | 148 | 0.020 |
Why?
|
| Codon, Nonsense | 1 | 2010 | 47 | 0.020 |
Why?
|
| Spasms, Infantile | 1 | 2010 | 39 | 0.020 |
Why?
|
| Vision, Ocular | 1 | 2010 | 73 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2010 | 287 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2010 | 144 | 0.020 |
Why?
|
| Eye | 1 | 2010 | 108 | 0.020 |
Why?
|
| Prostheses and Implants | 1 | 2010 | 121 | 0.020 |
Why?
|
| Introns | 1 | 2011 | 298 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2012 | 3450 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2012 | 679 | 0.020 |
Why?
|
| Intellectual Disability | 1 | 2010 | 196 | 0.020 |
Why?
|
| Pedigree | 1 | 2011 | 962 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2010 | 164 | 0.020 |
Why?
|
| Acute Disease | 1 | 2010 | 838 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2009 | 236 | 0.020 |
Why?
|
| Base Sequence | 1 | 2011 | 2207 | 0.020 |
Why?
|
| Graft Survival | 1 | 2010 | 939 | 0.020 |
Why?
|
| Genotype | 1 | 2011 | 1866 | 0.020 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2008 | 337 | 0.010 |
Why?
|
| Software | 1 | 2008 | 669 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2008 | 1849 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2008 | 4546 | 0.010 |
Why?
|